Oncologic and Functional Outcomes of Extended Curettage for Low-Grade Central Chondrosarcoma

Wan-Hyeong Cho; Soo-Yong Lee; Won-Seok Song; Chang-Bae Kong; Sang-Hyun Cho; Dae-Geun Jeon

doi:10.4055/jkoa.2011.46.5.351

Journal List > J Korean Orthop Assoc > v.46(5) > 1013092

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Cho, Lee, Song, Kong, Cho, and Jeon: Oncologic and Functional Outcomes of Extended Curettage for Low-Grade Central Chondrosarcoma

Original Article

Journal of the Korean Orthopaedic Association

Journal of the Korean Orthopaedic Association 2011; 46(5): 351-356.

Published online: 31 October 2011

DOI: https://doi.org/10.4055/jkoa.2011.46.5.351

Oncologic and Functional Outcomes of Extended Curettage for Low-Grade Central Chondrosarcoma

Wan-Hyeong Cho, M.D., Soo-Yong Lee, M.D., Won-Seok Song, M.D., Chang-Bae Kong, M.D., Sang-Hyun Cho, M.D., Dae-Geun Jeon, M.D.

Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Korea.

Correspondence to: Dae-Geun Jeon, M.D. Department of Orthopedic Surgery, Korea Cancer Center Hospital, 215-4, Gongneung-dong, Nowon-gu, Seoul 139-709, Korea. TEL: +82-2-970-1242 or 2176, FAX: +82-2-970-2403, dgjeon@kcch.re.kr

Received 1 September 2010 Accepted 7 June 2011

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

We analyzed the oncological and functional outcome of extended curettage for low-grade central chondrosarcoma.

Materials and Methods

We retrospectively reviewed 16 patients with Grade I central chondrosarcomas treated with extended curettage and adjuvant therapy of chemical cauterization with H₂O₂ at a minimum follow up of 24 months.

Results

Five-year disease free survival rate was 87.5%. Mean follow up was 82.7 months and no patient developed metastases or died of disease. The mean final Musculoskeletal Tumor Society functional score was 27.5 (91.6%).

Conclusion

Extended curettage is an effective treatment strategy for low-grade central chondrosarcoma with improved functional outcomes and lower complication rates compared to wide resection and reconstruction.

Keywords: central chondrosarcoma, low-grade, curettage

Figures and Tables

Figure 1

(A) Plain radiograph of a 52-year-old woman (Case 1) shows centrally located faint radiolucent and calcified lesion in distal metaphysis. (B) She was treated with curettage and bone cementation. (C) Histology of case 1 shows low cellularity and chondroid matrix (H&E, ×200). (D) After 7 months, pathologic fracture developed. (E) Open reduction & internal fixation was performed.

Figure 2

(A) Initial plain radiograph of a 51-year-old man (Case 8) shows mixed osteolytic and sclerotic lesion with calcifications in distal epi-metaphysis of right femur. (B) Histology of case 8 shows low cellularity and chondroid matrix (H&E, ×200). (C, D, E) He was treated with curettage and bone cementation, and after 14 months, local recurrence developed. (F) Re-curettage and bone cementation with ender-nail was performed.

Table 1

Demographic characteristics of 16 cases of low-grade chondrosarcoma

CDF, continuous disease free; NED, no evidence of disease.

Table 2

Comparative summery of oncologic results of low-grade chondrosarcoma

References

1. Campanacci M. Bone and soft tissue tumors. 1999. 2nd ed. Wien: Springer-Verlag;283.

2. Bruns J, Elbracht M, Niggemeyer O. Chondrosarcoma of bone: an oncological and functional follow-up study. Ann Oncol. 2001. 12:859–864.

3. Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT, Gannon FH. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics. 2003. 23:1245–1278.

4. Eriksson AI, Schiller A, Mankin HJ. The management of chondrosarcoma of bone. Clin Orthop Relat Res. 1980. (153):44–66.

5. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977. 40:818–831.

6. Fiorenza F, Abudu A, Grimer RJ, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br. 2002. 84:93–99.

7. van Loon CJ, Veth RP, Pruszczynski M, Wobbes T, Lemmens JA, van Horn J. Chondrosarcoma of bone: oncologic and functional results. J Surg Oncol. 1994. 57:214–221.

8. Lee FY, Mankin HJ, Fondren G, et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am. 1999. 81:326–338.

9. Healey JH, Lane JM. Chondrosarcoma. Clin Orthop Relat Res. 1986. (204):119–129.

10. Ahlmann ER, Menendez LR, Fedenko AN, Learch T. Influence of cryosurgery on treatment outcome of low-grade chondrosarcoma. Clin Orthop Relat Res. 2006. 451:201–207.

11. Bauer HC, Brosjö O, Kreicbergs A, Lindholm J. Low risk of recurrence of enchondroma and low-grade chondrosarcoma in extremities. 80 patients followed for 2-25 years. Acta Orthop Scand. 1995. 66:283–288.

12. McLoughlin GS, Sciubba DM, Wolinsky JP. Chondroma/Chondrosarcoma of the spine. Neurosurg Clin N Am. 2008. 19:57–63.

13. Alho A, Skjeldal S, Melvik JE, Pettersen EO, Larsen TE. The clinical importance of DNA synthesis and aneuploidy in bone and soft tissue tumours. Anticancer Res. 1993. 13:2383–2387.

14. Weiner SD. Enchondroma and chondrosarcoma of bone: clinical, radiologic, and histologic differentiation. Instr Course Lect. 2004. 53:645–649.

15. Gosheger G, Gebert C, Ahrens H, Streitbuerger A, Winkelmann W, Hardes J. Endoprosthetic reconstruction in 250 patients with sarcoma. Clin Orthop Relat Res. 2006. 450:164–171.

16. Normand AN, Cannon CP, Lewis VO, Lin PP, Yasko AW. Curettage of biopsy-diagnosed grade 1 periacetabular chondrosarcoma. Clin Orthop Relat Res. 2007. 459:146–149.

17. Schreuder HW, Pruszczynski M, Veth RP, Lemmens JA. Treatment of benign and low-grade malignant intramedullary chondroid tumours with curettage and cryosurgery. Eur J Surg Oncol. 1998. 24:120–126.

18. Suk SI, Lee CK, Ahn JK, et al. Orthopaedics. 2006. 6th ed. Seoul: Newest Medicine Company;311.

19. McDonald DJ, Sim FH, McLeod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg Am. 1986. 68:235–242.

20. Nicholson NC, Ramp WK, Kneisl JS, Kaysinger KK. Hydrogen peroxide inhibits giant cell tumor and osteoblast metabolism in vitro. Clin Orthop Relat Res. 1998. (347):250–260.

21. Gortzak Y, Kandel R, Deheshi B, et al. The efficacy of chemical adjuvants on giant-cell tumour of bone. An in vitro study. J Bone Joint Surg Br. 2010. 92:1475–1479.

22. Aarons C, Potter BK, Adams SC, Pitcher JD Jr, Temple HT. Extended intralesional treatment versus resection of low-grade chondrosarcomas. Clin Orthop Relat Res. 2009. 467:2105–2111.

23. Ozaki T, Lindner N, Hillmann A, Rödl R, Blasius S, Winkelmann W. Influence of intralesional surgery on treatment outcome of chondrosarcoma. Cancer. 1996. 77:1292–1297.

24. Marcove RC. A 17-year review of cryosurgery in the treatment of bone tumors. Clin Orthop Relat Res. 1982. (163):231–234.

25. Mohler DG, Chiu R, McCall DA, Avedian RS. Curettage and cryosurgery for low-grade cartilage tumors is associated with low recurrence and high function. Clin Orthop Relat Res. 2010. 468:2765–2773.

26. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993. (286):241–246.

27. Henderson ED, Dahlin DC. Chondrosarcoma of the bone -- a study of two hundred and eighty-eight cases. J Bone Joint Surg Am. 1963. 45:1450–1458.

28. Rizzo M, Ghert MA, Harrelson JM, Scully SP. Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome. Clin Orthop Relat Res. 2001. (391):224–233.

29. Tsuchiya H, Ueda Y, Morishita H, et al. Borderline chondrosarcoma of long and flat bones. J Cancer Res Clin Oncol. 1993. 119:363–368.

TOOLS

Similar articles